Origin.Bio Raises $15M in Funding

Origin.Bio, a Munich, Germany-based synthetic biology company, raised $15m in funding.

The round was led by EQT Ventures with participation from existing investor BlueYard Capital and new investors Taavet Hinrikus and Sten Tamkivi, Acequia Capital, Inventures and Charlie Songhurst.

The company intends to use the funds to expand the technology and team.

Founded by Jens Klein, CEO, Origin.Bio is a synthetic biology company which creates synthetic microorganisms that can make many of the same ingredients as traditional chemical industrialisation processes but with less energy requirements and waste produced.